PsychonautWiki Archive

3-MeO-PCP: Difference between revisions

← Older edit
>Tracer
m Added Category:Hallucinogen
>Larnaca
m Undo revision 166801 by Blackhole (talk)
 
(26 intermediate revisions by 18 users not shown)
Line 1: Line 1:
{{headerpanel|{{Warning/3-MeO-PCP}}}}
{{headerpanel|{{Warning/3-MeO-PCP}}}}
{{Distinguish|4-MeO-PCP}}
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/3-MeO-PCP}}
{{SubstanceBox/3-MeO-PCP}}
Line 5: Line 6:
'''3-Methoxyphencyclidine''' (also known as '''3-MeO-PCP''') is a lesser-known novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class. 3-MeO-PCP is a derivative of [[phencyclidine]] ('''PCP''') and is chemically related to substances like [[methoxetamine]] and [[3-MeO-PCE]]. It produces its effects by blocking [[NMDA receptor|NMDA receptors]] in the brain.  
'''3-Methoxyphencyclidine''' (also known as '''3-MeO-PCP''') is a lesser-known novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class. 3-MeO-PCP is a derivative of [[phencyclidine]] ('''PCP''') and is chemically related to substances like [[methoxetamine]] and [[3-MeO-PCE]]. It produces its effects by blocking [[NMDA receptor|NMDA receptors]] in the brain.  


3-MeO-PCP was first synthesized in 1979 in an investigation of [[phencyclidine]] (PCP) derivatives. However, its activity in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle reported qualitative similarities to [[PCP]] along with comparable potency.<ref name="PCP2MXE">Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref> In 2009, it began to be discussed on online forums such as bluelight.ru and was made available for sale on the [[research chemicals]] market.<ref>Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref>
3-MeO-PCP was first synthesized in 1979 in an investigation of [[phencyclidine]] (PCP) derivatives. However, its activity in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle reported qualitative similarities to [[PCP]] along with comparable potency.<ref name="Morris2014">{{cite journal | vauthors=((Morris, H.)), ((Wallach, J.)) | journal=Drug Testing and Analysis | title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs: PCP to MXE | volume=6 | issue=7–8 | pages=614–632 | date= July 2014 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.1620 | issn=19427603 | doi=10.1002/dta.1620}}</ref> In 2009, it began to be discussed on online forums such as bluelight.ru and was made available for sale on the [[research chemicals]] market.<ref name="Morris2014" />


Like other arylcyclohexlyamines, 3-MeO-PCP induces a state referred to as "[[dissociatives#Subjective effects|dissociative anesthesia]]", although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken [[orally]] and [[nasally]], although it may also be [[smoked]] and [[injected]]. It has been noted for its subtle come up and tendency to produce [[Delusions#Delusion of sobriety|delusions of sobriety]], which can lead to [[compulsive redosing]].
Like other arylcyclohexylamines, 3-MeO-PCP induces a state referred to as "[[dissociatives#Subjective effects|dissociative anesthesia]]", although the extent to which this occurs is reported to be highly dose-dependent and variable in its effects. It is commonly taken [[orally]] and [[nasally]], although it may also be [[smoked]] and [[injected]]. It has been noted for its subtle come up and tendency to produce [[Delusions#Delusion of sobriety|delusions of sobriety]], which can lead to [[compulsive redosing]].


Very little data exists for the pharmacology, metabolism, and toxicity of 3-MeO-PCP. Due to its potent hallucinogenic effects and lack of research, it is strongly advised to use use [[harm reduction practices]] if using this substance.
Very little data exists for the pharmacology, metabolism, and toxicity of 3-MeO-PCP. Due to its potent hallucinogenic effects and lack of research, it is strongly advised to use use [[harm reduction practices]] if using this substance.
Line 22: Line 23:
Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a "k-hole".
Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia and eventually the equivalent of a "k-hole".


3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter (SERT), 42 nM for the sigma-1 receptor and 2960 nM with H1 receptor <ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref> <ref name="&quot;AMCD&quot;">Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012</ref> It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.<ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref>
3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 42 nM for the sigma-1 receptor, 216 nM for the serotonin transporter (SERT), and 2960 nM with H1 receptor <ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref> <ref name="&quot;AMCD&quot;">{{Citation | title=Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | url=https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012}}</ref> It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP.<ref>http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984</ref> Like its sister compound PCP and unlike ketamine, 3-MeO-PCP shows a high affinity for inhibiting the relatively unstudied PCP2 glutamate receptor.{{Citation needed}}


Although 3-MeO-PCP was once claimed to possess opioid or dopaminergic activity,<ref name="chemist">Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist | http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2</ref> this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.<ref name="AMCD2">The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334</ref> 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a [[research chemical]] in 2011.<ref name="PCP2MXE" />
Although 3-MeO-PCP was once claimed to possess opioid or dopaminergic activity,<ref name="chemist">{{Citation | vauthors=((Morris, H.)) | year=2011 | title=Interview with a Ketamine Chemist | url=https://www.vice.com/en/article/ppzgk9/interview-with-ketamine-chemist-704-v18n2}}</ref> this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.<ref name="AMCD2">{{cite journal | vauthors=((Roth, B. L.)), ((Gibbons, S.)), ((Arunotayanun, W.)), ((Huang, X.-P.)), ((Setola, V.)), ((Treble, R.)), ((Iversen, L.)) | journal=PLOS ONE | title=The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | volume=8 | issue=3 | pages=e59334 | date=19 March 2013 | url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334 | issn=1932-6203 | doi=10.1371/journal.pone.0059334}}</ref> 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a [[research chemical]] in 2011.<ref name="Morris2014" />


==Subjective effects==
==Subjective effects==
3-MeO-PCP is commonly described as being more stimulating and less immobilizing than other [[dissociatives]] such as [[ketamine]] or [[MXE]]. At lower doses, it can induce sensory enhancements such as [[color enhancement]], [[acuity enhancement]], [[tactile enhancement]], [[auditory enhancement]] and [[bodily control enhancement]]. However, at medium to high doses, it presents sensory suppressions such as [[tactile suppression]], [[motor control loss]], [[auditory suppression]] and [[acuity suppression]]. Based on a large amount of experience reports, it appears to be considerably more likely to induce [[mania]], [[delusions]], and [[psychosis]] than other dissociatives (possibly due to its unusually high potency, [[compulsive redosing|compulsivity]] and erratic dose response).
3-MeO-PCP is commonly described as being more stimulating and less immobilizing than other [[dissociatives]] such as [[ketamine]] or [[MXE]].  
 
At lower doses, it can induce sensory enhancements such as [[color enhancement]], [[acuity enhancement]], [[tactile enhancement]], [[auditory enhancement]] and [[bodily control enhancement]]. At medium to high doses it presents sensory suppressions such as [[tactile suppression]], [[motor control loss]], [[auditory suppression]] and [[acuity suppression]].  
 
Based on a large amount of experience reports, it appears to be considerably more likely to induce [[mania]], [[delusions]], and [[psychosis]] than other dissociatives (possibly due to its unusually high potency, [[compulsive redosing|compulsivity]] and erratic dose response).
   
   
{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
{{effects/base
{{effects/base


Line 39: Line 45:
*'''[[Effect::Tactile enhancement]]''' or '''[[Effect::Tactile suppression]]''' - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [[pain relief|anesthesia]].
*'''[[Effect::Tactile enhancement]]''' or '''[[Effect::Tactile suppression]]''' - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [[pain relief|anesthesia]].
*'''[[Effect::Pain relief]]''' - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only in the stronger to heavier dose ranges.
*'''[[Effect::Pain relief]]''' - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only in the stronger to heavier dose ranges.
*'''[[Effect::Bodily control enhancement]]''' or '''[[Motor control loss]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards motor control  
*'''[[Effect::Bodily control enhancement]]''' or '''[[Motor control loss]]''' - At lower dosages this compound typically induces enhancements in bodily control. At higher dosages, this enhancement shifts towards motor control loss.
*'''[[Effect::Spatial disorientation]]''' - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.  
*'''[[Effect::Spatial disorientation]]''' - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.  
*'''[[Effect::Appetite suppression]]'''
*'''[[Effect::Appetite suppression]]''' or '''[[Effect::Appetite enhancement]]''' - The appetite suppression present with 3-MeO-PCP can be considered to be less sharp than with substances such as [[Cocaine]] and [[Ketamine]].  Like ketamine, this is due to the disconnection of electrical signals at high doses.  Unlike ketamine, it is also possible to experience a noticeable appetite enhancement that is less prominent than its sister compound [[PCP]].
*'''[[Effect::Nausea suppression]]'''
*'''[[Effect::Nausea suppression]]'''
*'''[[Effect::Restless legs]]'''
*'''[[Effect::Restless legs]]'''
Line 48: Line 54:
*'''[[Effect::Olfactory hallucination]]'''
*'''[[Effect::Olfactory hallucination]]'''
*'''[[Effect::Optical sliding]]'''
*'''[[Effect::Optical sliding]]'''
*'''[[Effect::Vibrating vision]]''' - At high doses, a person's eyeballs may begin to spontaneously wiggle back and forth in a rapid motion, causing the vision to become blurry and temporarily out of focus.<ref name="Berar et. al"/> This is a condition known as [http://en.wikipedia.org/wiki/Nystagmus nystagmus].
*'''[[Effect::Abnormal heartbeat]]'''
*'''[[Effect::Abnormal heartbeat]]'''
*'''[[Effect::Increased blood pressure]]'''{{citation needed}} - This effect is typically present at the higher doses.{{citation needed}}
*'''[[Effect::Increased blood pressure]]''' - This effect grows more pronounced with increased dose.<ref name="Berar et. al">{{cite journal | vauthors=((Berar, A.)), ((Allain, J.-S.)), ((Allard, S.)), ((Lefevre, C.)), ((Baert, A.)), ((Morel, I.)), ((Bouvet, R.)), ((Gicquel, T.)) | journal=Medicine | title=Intoxication with 3-MeO-PCP alone: A case report and literature review | volume=98 | issue=52 | pages=e18295 | date= December 2019 | url=https://journals.lww.com/10.1097/MD.0000000000018295 | issn=0025-7974 | doi=10.1097/MD.0000000000018295}}</ref>
*'''[[Effect::Increased heart rate]]'''{{citation needed}} - This effect has been reported as being more pronounced than other dissociatives, such as [[DCK]] or [[diphenidine]].
*'''[[Effect::Increased heart rate]]'''<ref name = "Berar et. al"/> - This effect has been reported as being more pronounced than other dissociatives, such as [[DCK]] or [[diphenidine]].
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Increased perspiration]]'''
*'''[[Effect::Dehydration]]'''
*'''[[Effect::Dehydration]]'''
Line 71: Line 78:
====Hallucinatory states====
====Hallucinatory states====
*'''[[Effect::Internal hallucination]]''' (''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'')
*'''[[Effect::Internal hallucination]]''' (''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'')


}}
}}
Line 96: Line 102:
*'''[[Effect::Thought deceleration]]'''
*'''[[Effect::Thought deceleration]]'''
*'''[[Effect::Increased libido]]''' - This is reported to be present at lower dosage ranges.  
*'''[[Effect::Increased libido]]''' - This is reported to be present at lower dosage ranges.  
====Suppressions====
*[[Effect::Addiction suppression]]
}}
}}
{{effects/auditory|
{{effects/auditory|
Line 120: Line 130:
{{#ask: [[Category:3-MeO-PCP]][[Category:Experience]]|format=ul|Columns=1}}
{{#ask: [[Category:3-MeO-PCP]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:
Additional experience reports can be found here:
* [https://www.erowid.org/experiences/subs/exp_3MeOPCP.shtml Erowid Experience Vaults: 3-MeO-PCP]
 
*[https://www.erowid.org/experiences/subs/exp_3MeOPCP.shtml Erowid Experience Vaults: 3-MeO-PCP]


==Toxicity and harm potential==
==Toxicity and harm potential==
{{Further|Research chemicals#Toxicity and harm potential}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
The toxicity and long-term health effects of recreational 3-MeO-PCP use has not been studied in any scientific context and the exact [[Toxicity::toxic dosage is unknown]]. This is because 3-MeO-PCP has very short history of human usage.  
The toxicity and long-term health effects of recreational 3-MeO-PCP use has not been studied in any scientific context and the exact [[Toxicity::toxic dosage is unknown]]. This is because 3-MeO-PCP has very short history of human usage.  


There is one death involving this substance recorded in the medical literature. In this case, the invidual's cause of death was determined to be from a combination of 3-MeO-PCP, [[amphetamine]], and [[diphenhydramine]].<ref>Bakota, E., Arndt, C., Romoser, A. A., & Wilson, S. K. (2016). Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method. Journal of Analytical Toxicology, 40(7), 504–510. http://doi.org/10.1093/jat/bkw056</ref>
There is one death involving this substance recorded in the medical literature. In this case, the individual's cause of death was determined to be from a combination of 3-MeO-PCP, [[amphetamine]], and [[diphenhydramine]].<ref>{{cite journal | vauthors=((Bakota, E.)), ((Arndt, C.)), ((Romoser, A. A.)), ((Wilson, S. K.)) | journal=Journal of Analytical Toxicology | title=Fatal Intoxication Involving 3-MeO-PCP: A Case Report and Validated Method | volume=40 | issue=7 | pages=504–510 | date= September 2016 | url=https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkw056 | issn=0146-4760 | doi=10.1093/jat/bkw056}}</ref>


===Dependence and abuse potential===
===Dependence and abuse potential===
Line 134: Line 145:


===Psychosis===
===Psychosis===
3-MeO-PCP has been reported to cause [[psychosis]], [[delusions]], and [[mania]] at a significantly higher rate than other [[dissociative]]s such as [[ketamine]], [[diphenidine]], or [[MXE]]. There are a large number of experience reports online which describe states of "psychotic delirium, amnesia, mania, and other serious consequences" after abusing 3-MeO-PCP.<ref name="three">The Big & Dandy 3-MeO-PCP Thread - Part 2 (Bluelight) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2</ref><ref name="two">The Big & Dandy 3-MeO-PCP Thread - Mad Manic Meo 3nity | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity</ref><ref name="one">The Big & Dandy 3-MeO-PCP Thread - Part 1 (Bluelight) | http://www.bluelight.org/vb/threads/454099-The-Big-amp-Dandy-3-MeO-PCP-Thread-%28Part-1%29</ref> In some cases, it has resulted in hospitalization and occasionally has taken up to a week or more to resolve.<ref name="six">Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/26295489</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 18 | 10-08-2014 09:10  | Post #448 by Sekio (Administrator) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12523821&viewfull=1#post12523821</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 20 | 30-08-2014 14:08 | Post #481 by Chocodoobie | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12559322&viewfull=1#post12559322</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 3 | Page 1 |  23-06-2015 11:53 | Post #5 by Confield | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity?p=13108675&viewfull=1#post13108675</ref><ref>https://www.erowid.org/experiences/exp.php?ID=103972 | NumbnDumb. "So Strong I'm Shocked: An Experience with 3-MeO-PCP (ID 103972)". Erowid.org. Jan 24, 2016. erowid.org/exp/103972</ref>
3-MeO-PCP has been reported to cause [[psychosis]], [[delusions]], and [[mania]] at a significantly higher rate than other [[dissociative]]s such as [[ketamine]], [[diphenidine]], or [[MXE]]. There are a large number of experience reports online which describe states of "psychotic delirium, amnesia, mania, and other serious consequences" after abusing 3-MeO-PCP.<ref name="three">The Big & Dandy 3-MeO-PCP Thread - Part 2 (Bluelight) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2</ref><ref name="two">The Big & Dandy 3-MeO-PCP Thread - Mad Manic Meo 3nity | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity</ref><ref name="one">The Big & Dandy 3-MeO-PCP Thread - Part 1 (Bluelight) | http://www.bluelight.org/vb/threads/454099-The-Big-amp-Dandy-3-MeO-PCP-Thread-%28Part-1%29</ref> In some cases, it has resulted in hospitalization and occasionally has taken up to a week or more to resolve.<ref name="six">{{cite journal | vauthors=((Bäckberg, M.)), ((Beck, O.)), ((Helander, A.)) | journal=Clinical Toxicology (Philadelphia, Pa.) | title=Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project | volume=53 | issue=9 | pages=856–864 | date= November 2015 | issn=1556-9519 | doi=10.3109/15563650.2015.1079325}}</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 18 | 10-08-2014 09:10  | Post #448 by Sekio (Administrator) | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12523821&viewfull=1#post12523821</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 2 | Page 20 | 30-08-2014 14:08 | Post #481 by Chocodoobie | http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2?p=12559322&viewfull=1#post12559322</ref><ref>The Big & Dandy 3-MeO-PCP Thread - Part 3 | Page 1 |  23-06-2015 11:53 | Post #5 by Confield | http://www.bluelight.org/vb/threads/760934-The-Big-amp-Dandy-3-MeO-PCP-Thread-Mad-Manic-Meo-3nity?p=13108675&viewfull=1#post13108675</ref><ref>{{Citation | title=3-MeO-PCP - Erowid Exp - “So Strong I’m Shocked” | url=https://www.erowid.org/experiences/exp.php?ID=103972}}</ref>


*Users should avoid taking 3-MeO-PCP for multiple days in a row or becoming dependent on it as this seems to be the main risk factor in the observed incidences of severe adverse effects.  
*Users should avoid taking 3-MeO-PCP for multiple days in a row or becoming dependent on it as this seems to be the main risk factor in the observed incidences of severe adverse effects.
*The recommended dosage range should not be exceeded as high doses can trigger these effects as well.  
*The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
*Users should start with extremely low doses and work their way up as slowly as possible. [[Volumetric liquid dosing|Volumetric liquid dosing]] should preferably be used due to the drug's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.
*Users should start with extremely low doses and work their way up as slowly as possible. [[Volumetric liquid dosing|Volumetric liquid dosing]] should preferably be used due to the drug's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.
*[[Compulsive redosing]] before one has fully sobered up is not recommended and can result in too high of a dose.
*[[Compulsive redosing]] before one has fully sobered up is not recommended and can result in too high of a dose.
Line 146: Line 157:


===Urinary tract effects===
===Urinary tract effects===
In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within [[ketamine]], but to a lesser extent. This is possibly because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:
In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within [[ketamine]], but to a lesser extent. This is possibly because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Increased urinary tract effects will compound with usage of other drugs like amphetamine even if the drugs are not simultaneously used.{{Citation needed}}  Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:


*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes.  
*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes.
*'''Urinary urgency''' - This can be described as a sudden, compelling need to urinate.
*'''Urinary urgency''' - This can be described as a sudden, compelling need to urinate.
*'''Urinary pressure''' - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
*'''Urinary pressure''' - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
Line 159: Line 170:
===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Dissos}}
{{DangerousInteractions/Dissos}}
*[[MDMA]]: 3-MeO-PCP acts as a mild serotonin releasing agent and could interact negatively with the serotonin release of MDMA


==Legal status==
==Legal status==
*'''Austria:''' 3-MeO-PCP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).{{citation needed}}
*'''Austria:''' 3-MeO-PCP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).{{citation needed}}
*'''Brazil:''' As of May 17, 2018, 25C-NBOH has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.<ref>List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial</ref>
*'''Brazil:''' As of May 17, 2018, 3-MeO-PCP has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.<ref>List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial</ref>
*'''Germany:''' On November 21, 2015, 3-MeO-PCP was added to "Anlage II" of the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.<ref>30. BtMÄndVO in Kraft getreten | http://blog.beck.de/2015/11/23/30-btm-ndvo-in-kraft-getreten-6-neue-stoffe-wurden-ins-btmg-aufgenommen-0</ref>
*'''Germany:''' On November 21, 2015, 3-MeO-PCP was added to "Anlage II" of the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.<ref>{{Citation | year=2015 | title=30. BtMÄndVO in Kraft getreten: 6 neue Stoffe wurden ins BtMG aufgenommen | url=https://community.beck.de/2015/11/23/30-btm-ndvo-in-kraft-getreten-6-neue-stoffe-wurden-ins-btmg-aufgenommen-0}}</ref>
*'''Denmark:''' As of August 25th, 2015, all MeO-PCP isomers (including 3-MeO-PCP) were added to the list of illegal substances in Denmark.<ref><nowiki>https://laegemiddelstyrelsen.dk/da/nyheder/2015/bekendtgoerelse-om-euforiserende-stoffer-ni-nye-stoffer-tilfoejet/</nowiki></ref>
*'''Denmark:''' As of August 25th, 2015, all MeO-PCP isomers (including 3-MeO-PCP) were added to the list of illegal substances in Denmark.<ref>{{Citation | title=Bekendtgørelse om euforiserende stoffer - ni nye stoffer tilføjet | url=https://laegemiddelstyrelsen.dk/da/nyheder/2015/bekendtgoerelse-om-euforiserende-stoffer-ni-nye-stoffer-tilfoejet/}}</ref>
*'''Sweden:''' Sweden's public health agency suggested classifying 3-MeO-PCP as a hazardous substance on November 10, 2014.<ref>Cannabinoider föreslås bli klassade som hälsofarlig vara | http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/</ref>
*'''Sweden:''' Sweden's public health agency suggested classifying 3-MeO-PCP as a hazardous substance on November 10, 2014.<ref>Cannabinoider föreslås bli klassade som hälsofarlig vara | http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/</ref>
*'''United Kingdom:''' 3-MeO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.<ref>The Misuse of Drugs Act 1971 (Amendment) Order 2013 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2013/239/introduction/made</ref>
*'''Switzerland:''' 3-MeO-PCP is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Turkey:''' 3-MeO-PCP is a classed as drug and is illegal to possess, produce, supply, or import.<ref name="Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742">{{Citation | title=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü | url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm}}</ref> <ref name="List of illegal substances for law"> https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf</ref>
*'''United Kingdom:''' 3-MeO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.<ref>{{Citation | title=The Misuse of Drugs Act 1971 (Amendment) Order 2013 | url=https://www.legislation.gov.uk/uksi/2013/239/introduction/made}}</ref>
*'''United States:''' 3-MeO-PCP is not a controlled substance in the United States but possession or distribution of 3-MeO-PCP for human use could potentially be prosecuted under the Federal Analogue Act due to its structural and pharmacological similarities to PCP.
*'''United States:''' 3-MeO-PCP is not a controlled substance in the United States but possession or distribution of 3-MeO-PCP for human use could potentially be prosecuted under the Federal Analogue Act due to its structural and pharmacological similarities to PCP.
*'''Czech Republic''': 3-MeO-PCP is a Schedule I controlled substance.<ref>{{Citation | vauthors=(([email protected], A. C.-)) | title=463/2013 Sb. Nařízení vlády o seznamech návykových látek | url=https://www.zakonyprolidi.cz/cs/2013-463}}</ref>
*'''The Netherlands''': 3-MeO-PCP is a Schedule I controlled substance.<ref>{{Citation| title=Opiumwet, Lijst I, (Dutch) | year=2023 | url=https://wetten.overheid.nl/BWBR0001941/2023-09-12#BijlageI}}</ref>
*'''Italy:''' 3-MeO-PCP is a Schedule I controlled substance.<ref>https://www.gazzettaufficiale.it/atto/vediMenuHTML?atto.dataPubblicazioneGazzetta=2021-10-18&atto.codiceRedazionale=21A06118&tipoSerie=serie_generale&tipoVigenza=originario</ref>


==See also==
==See also==
*[[Responsible use]]
*[[Responsible use]]
**[[Volumetric dosing]]
**[[Volumetric dosing]]
Line 180: Line 200:


==External links==
==External links==
*[https://en.wikipedia.org/wiki/3-MeO-PCP 3-MeO-PCP (Wikipedia)]
*[https://en.wikipedia.org/wiki/3-MeO-PCP 3-MeO-PCP (Wikipedia)]
*[https://erowid.org/chemicals/3-meo-pcp/ 3-MeO-PCP (Erowid Vault)]
*[https://erowid.org/chemicals/3-meo-pcp/ 3-MeO-PCP (Erowid Vault)]
Line 185: Line 206:


===Discussion and Media===
===Discussion and Media===
*[http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2 The Big & Dandy 3-MeO-PCP Thread (Bluelight)]
*[http://www.bluelight.org/vb/threads/697059-The-Big-amp-Dandy-3-MeO-PCP-Thread-Part-2 The Big & Dandy 3-MeO-PCP Thread (Bluelight)]
*[https://web.archive.org/web/20170111011440*/https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2 Interview with a Ketamine Chemist (VICE)]
*[https://web.archive.org/web/20170111011440*/https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2 Interview with a Ketamine Chemist (VICE)]


==Literature==
==Literature==
* Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
 
*Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620


==References==
==References==
{{reflist|2}}
{{reflist|2}}
[[Category:Psychoactive substance]]
[[Category:Psychoactive substance]]
[[Category:Research chemical]]
[[Category:Arylcyclohexylamine]]
[[Category:Arylcyclohexylamine]]
[[Category:Piperidine]]
[[Category:Piperidine]]
[[Category:Hallucinogen]]
[[Category:Dissociative]]
[[Category:Dissociative]]
[[Category:Research chemical]]


{{#set:Featured=true}}
{{#set:Featured=true}}
Retrieved from "http://psy.st/wiki/3-MeO-PCP"